Año: 2022
Journal Impact Factor (JIF): 7,4
Categoría | Edición | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|---|
ONCOLOGY | SCIE | 43/241 | Q1 | T1 | D2 |
Año: 2022
Journal Citation Indicator (JCI): 1,330
Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
---|---|---|---|---|---|
ONCOLOGY | 49/318 | Q1 | T1 | D2 | 84,75 |
Año:
2022
CiteScore:
13,800
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Oncology | 35/366 | Q1 | T1 | D1 |
Cancer Research | 29/214 | Q1 | T1 | D2 |
SJR año:
2022
Factor de Impacto:
2,408
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Cancer Research | 29/220 | Q1 | T1 | D2 |
Oncology | 39/375 | Q1 | T1 | D2 |
Agencia | Código de Proyecto |
---|---|
Astex Pharmaceuticals | - |
Novartis | - |
Novartis Institutes for BioMedical Research | - |
The study was sponsored by Novartis. We thank the patients who participated in this trial, their families, and their caregivers; members of the data monitoring committee; members of the study steering committee; staff members who helped with the trial at e | - |
# | Autor | Afiliación |
---|---|---|
1 | KU Leuven– University Hospital Leuven (Belgium) | |
2 | Fasching, P. A. | Universitätsklinik Erlangen und Medizinische Fakultät (Germany) |
3 | Chia, S. | British Columbia Cancer Agency (Canada) |
4 | Jerusalem, G. | Centre Hospitalier Universitaire de Liege (Belgium) |
5 | De Laurentiis, M. | Istituto Nazionale Tumori IRCCS - Fondazione G Pascale, Napoli (Italy) |
6 | Im, S. A. | Seoul National University Hospital (South Korea) |
7 | Petrakova, K. | Masaryk Memorial Cancer Institute (Czech Republic) |
8 | Bianchi, G. V. | Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy) |
9 | Martín, M. | Universidad Complutense de Madrid (Spain) |
10 | Nusch, A. | Practice for Hematology and Internal Oncology (Germany) |
11 | Sonke, G. S. | The Netherlands Cancer Institute (Netherlands) |
12 | De la Cruz-Merino, L. | Hospital Universitario Virgen Macarena (Spain) |
13 | Beck, J. T. | Highlands Oncology (United States) |
14 | Zarate, J. P. | Novartis International AG (Switzerland) |
15 | Wang, Y. | Novartis International AG (Switzerland) |
16 | Chakravartty, A. | Novartis International AG (Switzerland) |
17 | Wang, C. | Novartis International AG (Switzerland) |
18 | Slamon, D. J. | David Geffen School of Medicine at UCLA (United States) |